<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941128-2-00080</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2. The trustee shall have the power and authority to assure Respondent's compliance with the terms of Paragraph II of this Order and with the Divestiture Agreement with the Acquirer or the New Acquirer, as applicable. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Within ten (10) days after appointment of the trustee, AHP shall execute a trust agreement that, subject to the prior approval of the Commission, confers on the trustee all the rights and powers necessary to permit the trustee to assure Respondent's compliance with the terms of Paragraph II of this Order and with the Divestiture Agreement with the Acquirer or the New Acquirer, as applicable. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. The trustee shall serve until such time as the Acquirer or the New Acquirer, as applicable, has received all necessary FDA approvals to manufacture Tetanus and Diphtheria Vaccines for sale in the United States, or for fifteen years, whichever is shorter. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. The trustee shall have full and complete access to the personnel, books, records, facilities and technical information related to the manufacture of AHP's Tetanus and Diphtheria Vaccines, or to any other relevant information, as the trustee may reasonably request, including but not limited to all records kept in the normal course of business that relate to the cost of manufacturing Tetanus and Diphtheria Vaccines. Respondent shall cooperate with any reasonable request of the trustee. Respondent shall take no action to interfere with or impede the trustee's ability to assure Respondent's compliance with Paragraph II of this Order and the Divestiture Agreement with the Acquirer or the New Acquirer, as applicable. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 6. The trustee shall serve, without bond or other security, at the cost and expense of AHP, on such reasonable and customary terms and conditions as the Commission may set. The trustee shall have authority to employ, at the cost and expense of AHP, such consultants, accountants, attorneys and other representatives and assistants as are reasonably necessary to carry out the trustee's duties and responsibilities. The trustee shall account for all expenses incurred. The Commission shall approve the account of the trustee, including fees for his or her services. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 7. Respondent shall indemnify the trustee and hold the trustee harmless against any losses, claims, damages, liabilities, or expenses arising out of, or in connection with, the performance of the trustee's duties, including all reasonable fees of counsel and other expenses incurred in connection with the preparations for, or defense of any claim whether or not resulting in any liability, except to the extent that such liabilities, losses, damages, claims, or expenses result from the misfeasance, gross negligence, willful or wanton acts, or bad faith by the trustee. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 8. If the trustee ceases to act or fails to act diligently, a substitute trustee shall be appointed in the same manner as provided in Paragraph III of this Order. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 9. The commission may on its own initiative or at the request of the trustee issue such additional orders or directions as may be necessary or appropriate to assure compliance with the requirements of Paragraph II of this Order and the Divestiture Agreement with the Acquirer or the New Acquirer, as applicable. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 10. The trustee shall evaluate reports submitted to it by the Acquirer or the New Acquirer, as applicable, with respect to the efforts of the Acquirer or the New Acquirer, as applicable, to obtain all necessary FDA approvals to manufacture Tetanus and Diphtheria Vaccines for sale in the United States and shall report in writing to the Commission every six months concerning compliance by the Respondent and the Acquirer or the New Acquirer, as applicable, with the provisions of Paragraph II of this Order and the efforts of the Acquirer or the New Acquirer, as applicable, to receive all necessary FDA approvals to manufacture Tetanus and Diphtheria Vaccines for sale in the United States. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Respondent shall comply with all reasonable directives of the trustee regarding: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Respondent's obligations to contract manufacture and deliver the Acquirer's requirements or the New Acquirer's requirements, as applicable, for Tetanus and Diphtheria Vaccines, pursuant to Paragraphs II.C.1 and II.C.2 of this Order; <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Respondent's obligations to provide representations and warranties regarding Tetanus and Diphtheria Vaccines, pursuant to Paragraph II.C.4 of this Order; and <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Respondent's obligations to provide information, technical assistance and advice, pursuant to Paragraph II.C.6 of this Order. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. If the Commission terminates the Divestiture Agreement pursuant to Paragraph II.C.10, the Commission may direct the trustee to seek a New Acquirer, as provided for in Paragraph IV of this Order. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            